Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Reported Saturday, Kura Oncology Presents New ESMO 2025 Data Showing Darlifarnib Plus Cabozantinib Delivers 50% ORR In RCC; FTI Programs Demonstrate Robust Activity And Manageable Safety Profile

Author: Benzinga Newsdesk | October 20, 2025 04:19am
  • FTI mechanism addresses innate and adaptive resistance pathways common to targeted oncology therapies
  • Early clinical and preclinical data support darlifarnib's potential to enhance clinical benefit of PI3Kα-, KRAS- and tyrosine kinase inhibitors
  • 50% objective response rate and 80% disease control rate in renal cell carcinoma (RCC) cohort of darlifarnib plus cabozantinib in ongoing dose-escalation clinical trial

Posted In: KURA


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist